share_log

BioVie | PRE 14A: Preliminary proxy statements relating to merger or acquisition

BioVie | PRE 14A: Preliminary proxy statements relating to merger or acquisition

BioVie | PRE 14A：并购重组委托声明
美股SEC公告 ·  2024/09/17 14:00

Moomoo AI 已提取核心信息

BioVie Inc., a Nevada corporation, announced the filing of a PRE 14A preliminary proxy statement with the SEC, detailing the upcoming virtual Annual Meeting of Stockholders scheduled for November 7, 2024. The meeting will address the election of six directors, the ratification of EisnerAmper LLP as the independent registered public accounting firm for the 2025 fiscal year, an advisory vote on executive compensation, and the approval of an amendment to the 2019 Omnibus Equity Incentive Plan. The Board of Directors has recommended voting in favor of all proposals. Stockholders of record as of September 30, 2024, are entitled to participate and vote at the meeting, which will be conducted online due to the inability to attend in person. The proxy materials, including the 2024 Annual Report and Proxy Statement, will be available on BioVie's website and mailed to stockholders around October 9, 2024.
BioVie Inc., a Nevada corporation, announced the filing of a PRE 14A preliminary proxy statement with the SEC, detailing the upcoming virtual Annual Meeting of Stockholders scheduled for November 7, 2024. The meeting will address the election of six directors, the ratification of EisnerAmper LLP as the independent registered public accounting firm for the 2025 fiscal year, an advisory vote on executive compensation, and the approval of an amendment to the 2019 Omnibus Equity Incentive Plan. The Board of Directors has recommended voting in favor of all proposals. Stockholders of record as of September 30, 2024, are entitled to participate and vote at the meeting, which will be conducted online due to the inability to attend in person. The proxy materials, including the 2024 Annual Report and Proxy Statement, will be available on BioVie's website and mailed to stockholders around October 9, 2024.
美国BioVie股份有限公司宣布向美国证券交易委员会提交了一份关于即将在2024年11月7日举行的虚拟股东年度大会的预备性委托代理声明PRE 14A。该次会议将讨论选举六名董事，批准EisnerAmper LLP作为2025财年独立注册会计师事务所，就高管薪酬进行咨询性投票，并批准对2019年全权奖励计划进行修改。董事会建议全票投赞成所有提案。截至2024年9月30日的股东名单有权参加和投票参加这次会议，由于不能亲自参加，本次会议将在线上进行。委托代理材料，包括2024年年度报告和委托代理声明，将在BioVie公司的网站上提供，并在2024年10月9日左右寄给股东。
美国BioVie股份有限公司宣布向美国证券交易委员会提交了一份关于即将在2024年11月7日举行的虚拟股东年度大会的预备性委托代理声明PRE 14A。该次会议将讨论选举六名董事，批准EisnerAmper LLP作为2025财年独立注册会计师事务所，就高管薪酬进行咨询性投票，并批准对2019年全权奖励计划进行修改。董事会建议全票投赞成所有提案。截至2024年9月30日的股东名单有权参加和投票参加这次会议，由于不能亲自参加，本次会议将在线上进行。委托代理材料，包括2024年年度报告和委托代理声明，将在BioVie公司的网站上提供，并在2024年10月9日左右寄给股东。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Sana Biotechnology
    SANA
    -- 4.835
    Silo Pharma
    SILO
    -- 1.911
    Vir Biotechnology
    VIR
    -- 13.684
    Compass Therapeutics
    CMPX
    -- 1.855
    NLS Pharmaceutics
    NLSP
    -- 2.5850

    解锁榜首股票